The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation

European Journal of Anaesthesiology

Volumn 33, Issue 5, 2016, Pages 361-367

  Martin, Anne Céline ^a,b,c   Berndt, Célia ^a,b   Calmette, Leyla ^a,b,d   Philip, Ivan ^e   Decouture, Benoit ^a,b   Gaussem, Pascale ^a,b,f   Gouin Thibault, Isabelle ^a,b,d   Samama, Charles Marc ^a,b,d   Bachelot Loza, Christilla ^a,b   Godier, Anne ^a,b,g  

^a Fondation Carpentier   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c University of Paris Descartes   (France)

^d Laboratoire d'hématologie ^*  (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; TICAGRELOR; ADENOSINE; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; IMPEDANCE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; MALE; OUTCOME ASSESSMENT; PLATELET SUPPLEMENTATION; SUPPLEMENTATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CASE REPORT; DRUG EFFECTS; MIDDLE AGED;

ADENOSINE; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; ASPIRIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION;

EID: 84963930793     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0000000000000348     Document Type: Article

References (26)

1. Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets 2013; 24: 615-624
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: 2645-2687
4. Windecker S, Hernandez-Antolin RA, Stefanini GG, et al. Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention 2014; 10 (Suppl T): T23-T31
5. Hansson EC, Rexius H, Dellborg M, et al. Coronary artery bypass graftingrelated bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardiothorac Surg 2014; 46: 699-705
6. Brilique. Summary of product characteristics; 2015. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001241/WC500100494.pdf. Accessed July 2015
7. Hansson EC, Shams Hakimi C, Astrom-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014; 112: 570-575
8. Hobl EL, Derhaschnig U, Firbas C, et al. Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor. Eur J Clin Invest 2013; 43: 1258-1261
9. Scharbert G, Wetzel L, Schrottmaier WC, et al. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion 2015; 55: 1320-1326
10. Bonhomme F, Bonvini R, Reny JL, et al. Impact of noninhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study. Platelets 2015; 26: 324-330
11. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015; 372: 196-197
12. Cazenave JP, Ohlmann P, Cassel D, et al. Gachet C: Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004; 272: 13-28
13. Sheriff J, Girdhar G, Chiu WC, et al. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device. J Thromb Thrombolysis 2014; 37: 499-506
14. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856
15. Karazniewicz-Lada M, Danielak D, Burchardt P, et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet 2014; 53: 155-164
16. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014; 34: 1077-1090
17. Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013; 73: 1681-1709
18. Ranucci M, Baryshnikova E, Soro G, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91: 123-129
19. Sugidachi A, Ohno K, Ogawa T, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol 2013; 169: 82-89
20. Femia EA, Scavone M, Lecchi A, Cattaneo M. Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate analyzer) and with light transmission aggregometry. J Thromb Haemost 2013; 11: 2193-2196
21. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007; 92: 694-697
22. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585
23. Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood 2015; 125: 3484-3490
24. Li C, Hirsh J, Xie C, et al. Reversal of the antiplatelet effects of aspirin and clopidogrel. J Thromb Haemost 2012; 10: 521-528
25. Taylor G, Osinski D, Thevenin A, Devys JM. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg 2013; 74: 1367-1369
26. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382